Global pharmaceutical trade reached an annual export valuation of $1.8 trillion in 2024, cementing medicines as one of the world's most strategically significant traded commodities. Within that landscape, Ireland occupies a position of extraordinary weight. Ireland exported €100 billion in pharmaceuticals in 2024, ranking second in the EU behind Germany and ahead of Belgium and the Netherlands. That a country of 5.5 million people accounts for such a share of global medicine supply reflects decades of deliberate industrial policy. It also reflects a concentration risk that procurement leaders, in both the public and private sectors, have been slow to price into their planning frameworks.

The scale of Ireland's pharmaceutical trade is not incidental. It is structural. By 2025, pharmaceutical products represented 53% of Irish goods exports, with pharma exports reaching a record 41% of modified national income. Twenty-seven of the world's thirty largest pharmaceutical companies operate manufacturing facilities on the island. That depth of integration means that disruptions to Ireland's export capacity, or to access to the Irish market, carry consequences that reach well beyond national trade statistics and into the medicine supply chains of hospitals and health systems globally.

Three procurement responses are both specific and attainable. First, public health procurement bodies should conduct an immediate audit of their top 50 medicines by volume against country-of-manufacture data, identifying which products are sourced exclusively from single-country facilities. Second, procurement frameworks for pharmaceutical supply should incorporate mandatory supplier disclosure of alternative manufacturing site capacity, treating geographic concentration as a scored risk criterion at tender stage. Third, the Health Service Executive and equivalent UK bodies should align with Enterprise Ireland's supply chain resilience programmes to co-invest in dual-sourcing arrangements for high-volume generic medicines, reducing dependence on any single export hub.

The OEC pharmaceutical trade data makes Ireland's centrality to global medicine supply impossible to overlook. What it also reveals is that centrality and resilience are not the same thing. Procurement leaders who treat Ireland's pharmaceutical dominance as a guarantee of supply security, rather than as a concentration risk requiring active management, are reading the data in the wrong direction.

(The views expressed by the writer are his/her own and do not necessarily reflect the views or positions of BusinessRiver.)